Cargando…

Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells

BACKGROUND: We previously identified platelet-activating factor receptor (PAFR) as being overexpressed in ovarian cancer and found that its ligand PAF evoked EGFR phosphorylation using the phospho-antibody microarray. Epidermal growth factor receptor (EGFR) are also overexpressed in ovarian cancer a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yi, Zhang, Mingxing, Zhang, Xiaoyan, Cai, Qingqing, Zhu, Zhiling, Jiang, Wei, Xu, Congjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189590/
https://www.ncbi.nlm.nih.gov/pubmed/25261977
http://dx.doi.org/10.1186/s13046-014-0085-6
_version_ 1782338385981997056
author Yu, Yi
Zhang, Mingxing
Zhang, Xiaoyan
Cai, Qingqing
Zhu, Zhiling
Jiang, Wei
Xu, Congjian
author_facet Yu, Yi
Zhang, Mingxing
Zhang, Xiaoyan
Cai, Qingqing
Zhu, Zhiling
Jiang, Wei
Xu, Congjian
author_sort Yu, Yi
collection PubMed
description BACKGROUND: We previously identified platelet-activating factor receptor (PAFR) as being overexpressed in ovarian cancer and found that its ligand PAF evoked EGFR phosphorylation using the phospho-antibody microarray. Epidermal growth factor receptor (EGFR) are also overexpressed in ovarian cancer and contribute to the growth of ovarian cancer cells. Here, we investigated the mechanisms of crosstalk between PAFR and EGFR signaling in ovarian cancer cells to further determine whether the interaction between PAFR and EGFR synergistic contribute to the progression of ovarian cancer. METHODS: Expression and localization of PAFR in several ovarian cancer cell lines were assessed by Western blot, realtime-PCR and immunofluorescence. The ovarian cancer cells were stimulated with PAF or PAF and in some experiments also pharmacological inhibitors. Phosphorylation of proteins in signaling pathways were measured by Western blot. HB-EGF concentrations of the supernatant from stimulated ovarian cancer cells were measured by enzyme-linked immunosorbent assay. RESULTS: Our data show that PAF increases EGFR phosphorylation through PAFR in a time- and dose- dependent manner in SKOV-3 ovarian cancer cells. This transactivation is dependent on phospholipase C-β and intracellular calcium signaling. This pathway is also Src tyrosine kinase- and metalloproteinase- dependent. PAF triggers EGFR activation through the increased heparin-binding EGF-like growth factor (HB-EGF) release in metalloprotease-dependent manner. Several studies involving EGFR transactivation through G-protein coupled receptor (GPCR) have demonstrated EGFR-dependent increase in ERK1/2 phosphorylation. Yet in SKOV-3 cells, PAF treatment also increases ERK1/2 phosphorylation in a EGFR-independent manner. CONCLUSIONS: The results suggest that in SKOV-3 ovarian cancer cells, PAF transactivates EGFR and downstream ERK pathways, thus diversifying the GPCR-mediated signal. The crosstalk between PAFR and EGFR suggests a potentially important signaling linkage between inflammatory and growth factor signaling in ovarian cancer cells.
format Online
Article
Text
id pubmed-4189590
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41895902014-10-09 Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells Yu, Yi Zhang, Mingxing Zhang, Xiaoyan Cai, Qingqing Zhu, Zhiling Jiang, Wei Xu, Congjian J Exp Clin Cancer Res Research BACKGROUND: We previously identified platelet-activating factor receptor (PAFR) as being overexpressed in ovarian cancer and found that its ligand PAF evoked EGFR phosphorylation using the phospho-antibody microarray. Epidermal growth factor receptor (EGFR) are also overexpressed in ovarian cancer and contribute to the growth of ovarian cancer cells. Here, we investigated the mechanisms of crosstalk between PAFR and EGFR signaling in ovarian cancer cells to further determine whether the interaction between PAFR and EGFR synergistic contribute to the progression of ovarian cancer. METHODS: Expression and localization of PAFR in several ovarian cancer cell lines were assessed by Western blot, realtime-PCR and immunofluorescence. The ovarian cancer cells were stimulated with PAF or PAF and in some experiments also pharmacological inhibitors. Phosphorylation of proteins in signaling pathways were measured by Western blot. HB-EGF concentrations of the supernatant from stimulated ovarian cancer cells were measured by enzyme-linked immunosorbent assay. RESULTS: Our data show that PAF increases EGFR phosphorylation through PAFR in a time- and dose- dependent manner in SKOV-3 ovarian cancer cells. This transactivation is dependent on phospholipase C-β and intracellular calcium signaling. This pathway is also Src tyrosine kinase- and metalloproteinase- dependent. PAF triggers EGFR activation through the increased heparin-binding EGF-like growth factor (HB-EGF) release in metalloprotease-dependent manner. Several studies involving EGFR transactivation through G-protein coupled receptor (GPCR) have demonstrated EGFR-dependent increase in ERK1/2 phosphorylation. Yet in SKOV-3 cells, PAF treatment also increases ERK1/2 phosphorylation in a EGFR-independent manner. CONCLUSIONS: The results suggest that in SKOV-3 ovarian cancer cells, PAF transactivates EGFR and downstream ERK pathways, thus diversifying the GPCR-mediated signal. The crosstalk between PAFR and EGFR suggests a potentially important signaling linkage between inflammatory and growth factor signaling in ovarian cancer cells. BioMed Central 2014-09-28 /pmc/articles/PMC4189590/ /pubmed/25261977 http://dx.doi.org/10.1186/s13046-014-0085-6 Text en © Yu et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yu, Yi
Zhang, Mingxing
Zhang, Xiaoyan
Cai, Qingqing
Zhu, Zhiling
Jiang, Wei
Xu, Congjian
Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells
title Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells
title_full Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells
title_fullStr Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells
title_full_unstemmed Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells
title_short Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells
title_sort transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189590/
https://www.ncbi.nlm.nih.gov/pubmed/25261977
http://dx.doi.org/10.1186/s13046-014-0085-6
work_keys_str_mv AT yuyi transactivationofepidermalgrowthfactorreceptorthroughplateletactivatingfactorreceptorinovariancancercells
AT zhangmingxing transactivationofepidermalgrowthfactorreceptorthroughplateletactivatingfactorreceptorinovariancancercells
AT zhangxiaoyan transactivationofepidermalgrowthfactorreceptorthroughplateletactivatingfactorreceptorinovariancancercells
AT caiqingqing transactivationofepidermalgrowthfactorreceptorthroughplateletactivatingfactorreceptorinovariancancercells
AT zhuzhiling transactivationofepidermalgrowthfactorreceptorthroughplateletactivatingfactorreceptorinovariancancercells
AT jiangwei transactivationofepidermalgrowthfactorreceptorthroughplateletactivatingfactorreceptorinovariancancercells
AT xucongjian transactivationofepidermalgrowthfactorreceptorthroughplateletactivatingfactorreceptorinovariancancercells